CVE Vulnerabilities

CVE-2020-10627

Improper Access Control

Published: Dec 01, 2021 | Modified: Nov 21, 2024
CVSS 3.x
8.1
HIGH
Source:
NVD
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
CVSS 2.x
4.8 MEDIUM
AV:A/AC:L/Au:N/C:P/I:P/A:N
RedHat/V2
RedHat/V3
Ubuntu

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Weakness

The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor.

Affected Software

Name Vendor Start Version End Version
Omnipod_insulin_management_system_firmware Insulet - (including) - (including)

Extended Description

Access control involves the use of several protection mechanisms such as:

When any mechanism is not applied or otherwise fails, attackers can compromise the security of the product by gaining privileges, reading sensitive information, executing commands, evading detection, etc. There are two distinct behaviors that can introduce access control weaknesses:

Potential Mitigations

  • Compartmentalize the system to have “safe” areas where trust boundaries can be unambiguously drawn. Do not allow sensitive data to go outside of the trust boundary and always be careful when interfacing with a compartment outside of the safe area.
  • Ensure that appropriate compartmentalization is built into the system design, and the compartmentalization allows for and reinforces privilege separation functionality. Architects and designers should rely on the principle of least privilege to decide the appropriate time to use privileges and the time to drop privileges.

References